NO940370D0 - Anvendelse av interleukin-10-analoger eller -antagonister til behandling av endotoksin- eller superantigenindusert toksisitet - Google Patents

Anvendelse av interleukin-10-analoger eller -antagonister til behandling av endotoksin- eller superantigenindusert toksisitet

Info

Publication number
NO940370D0
NO940370D0 NO940370A NO940370A NO940370D0 NO 940370 D0 NO940370 D0 NO 940370D0 NO 940370 A NO940370 A NO 940370A NO 940370 A NO940370 A NO 940370A NO 940370 D0 NO940370 D0 NO 940370D0
Authority
NO
Norway
Prior art keywords
interleukin
superantigen
antagonists
analogs
induced toxicity
Prior art date
Application number
NO940370A
Other languages
English (en)
Other versions
NO315409B1 (no
NO940370L (no
Inventor
De Malefyt Rene Waal
Maureen Howard
Di-Hwei Hsu
Hiroshi Ishida
Anne O'garra
Hergen Spits
Albert Zlotnik
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO940370L publication Critical patent/NO940370L/no
Publication of NO940370D0 publication Critical patent/NO940370D0/no
Publication of NO315409B1 publication Critical patent/NO315409B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
NO19940370A 1991-08-06 1994-02-04 Anvendelse av interleukin-10 eller en analog, agonist eller antagonist derav ved fremstillingen av et farmasöytisk preparat for modulering avbetennelse eller T-celleformidlet immunfunksjon NO315409B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74212991A 1991-08-06 1991-08-06
PCT/US1992/006378 WO1993002693A2 (en) 1991-08-06 1992-08-06 Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity

Publications (3)

Publication Number Publication Date
NO940370L NO940370L (no) 1994-02-04
NO940370D0 true NO940370D0 (no) 1994-02-04
NO315409B1 NO315409B1 (no) 2003-09-01

Family

ID=24983602

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19940370A NO315409B1 (no) 1991-08-06 1994-02-04 Anvendelse av interleukin-10 eller en analog, agonist eller antagonist derav ved fremstillingen av et farmasöytisk preparat for modulering avbetennelse eller T-celleformidlet immunfunksjon

Country Status (17)

Country Link
EP (2) EP0541214A3 (no)
JP (3) JPH07502019A (no)
KR (1) KR100271197B1 (no)
AT (1) ATE187336T1 (no)
AU (1) AU678137B2 (no)
CA (1) CA2115060C (no)
CZ (1) CZ281796B6 (no)
DE (1) DE69230403T2 (no)
DK (1) DK0600970T3 (no)
ES (1) ES2138976T3 (no)
FI (1) FI940519L (no)
GR (1) GR3032167T3 (no)
HU (1) HU224437B1 (no)
NO (1) NO315409B1 (no)
PT (1) PT600970E (no)
SK (1) SK282947B6 (no)
WO (1) WO1993002693A2 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3801193A (en) * 1992-03-20 1993-10-21 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
EP0667789A1 (en) * 1992-09-18 1995-08-23 Schering Corporation Restoration of immunocompetency to t helper cells in hiv infected patients
AU6000894A (en) * 1993-02-01 1994-08-29 Michel Goldman Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
IL110413A0 (en) * 1993-07-26 1994-10-21 Schering Corp Agonists and antagonists of human interleukin-10
US6159937A (en) * 1994-07-05 2000-12-12 Steeno Research Group A/S Immunomodulators
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
WO2002066069A1 (en) * 2001-02-20 2002-08-29 Kansai Technology Licensing Organization Co., Ltd. Remedies for inflammatory/tumor diseases
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
CN102711829B (zh) 2009-11-30 2016-03-16 生物测试股份公司 治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
EP2986990B1 (en) 2013-03-20 2018-08-15 F.Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
DE69013011T2 (de) * 1989-12-20 1995-02-23 Schering Corp., Kenilworth, N.J. Bcrf1-proteine als inhibitoren von interferon-g(g).

Also Published As

Publication number Publication date
EP0541214A2 (en) 1993-05-12
PT600970E (pt) 2000-05-31
SK282947B6 (sk) 2003-01-09
NO315409B1 (no) 2003-09-01
CA2115060C (en) 2003-05-06
DE69230403D1 (de) 2000-01-13
JP2004250454A (ja) 2004-09-09
DK0600970T3 (da) 2000-05-29
HU224437B1 (hu) 2005-09-28
DE69230403T2 (de) 2000-05-11
FI940519A7 (fi) 1994-02-04
GR3032167T3 (en) 2000-04-27
NO940370L (no) 1994-02-04
CZ281796B6 (cs) 1997-02-12
JPH07502019A (ja) 1995-03-02
WO1993002693A2 (en) 1993-02-18
CZ24394A3 (en) 1995-01-18
HUT66865A (en) 1995-01-30
JP2008013573A (ja) 2008-01-24
ES2138976T3 (es) 2000-02-01
FI940519A0 (fi) 1994-02-04
EP0600970A1 (en) 1994-06-15
CA2115060A1 (en) 1993-02-18
WO1993002693A3 (en) 1993-07-22
FI940519L (fi) 1994-02-04
EP0600970B1 (en) 1999-12-08
ATE187336T1 (de) 1999-12-15
HU9400314D0 (en) 1994-05-30
AU678137B2 (en) 1997-05-22
EP0541214A3 (en) 1993-09-08
AU2441192A (en) 1993-03-02
KR100271197B1 (ko) 2000-11-01
SK12994A3 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
GR3024421T3 (en) Benzenesulfonamide derivative
DE69304955D1 (de) Behandlung von neurodegenerativen Erkrankungen
BG60249B1 (bg) Тиазолово съединение за лечение на язви
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
DE69213998D1 (de) Dehalogenierung von Organohalogen enthaltenden Verbindungen
NO940370L (no) Anvendelse av interleukin-10-analoger eller -antagonister til behandling av endotoksin- eller superantigenindusert toksisitet
FI933193A0 (fi) Behandling av neoplastisk sjukdom med interleukin-10
ES2156120T3 (es) Derivados arilamidicos.
EP0238553A4 (en) TREATMENT OF A CATABOLIC DEREGULATION.
DE69102936D1 (de) Bis(alkyl-substituierte-4-hydroxyphenylthio)alkan-Analoga als Inhibitoren der Kataraktentstehung.
ATE125704T1 (de) Behandlung neurodegenerativer erkrankungen.
GR3022097T3 (en) Method and compositions for treating injury
FI933739A0 (fi) Foerfarande och komposition foer kontrollering av mikroorganismtillvaext
DE3788035D1 (de) Etodolac zur Hemmung von Gelenkversteifung.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees